文献速递类风湿关节炎

类风湿关节炎患者急性冠脉事件后的长期结局与二级预防

Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-08-20

基于1135例RA和3184例非RA的急性冠脉综合征(ACS)患者队列,评估1年及全程(平均2年)随访的ACS复发与死亡风险。RA患者ACS复发和死亡风险均升高,且在校正基线合并症后仍显著,该风险增加不能仅由二级预防药物使用差异解释。

要点

  • RA患者ACS后1年复发风险HR=1.30(95%CI 1.04–1.62),死亡风险HR=1.38(95%CI 1.20–1.59)。
  • 全程随访(平均2年)复发风险HR=1.27(95%CI 1.06–1.52),死亡风险HR=1.50(95%CI 1.34–1.68)。
  • 充分启用并坚持二级预防治疗的亚组中,RA患者复发和死亡风险仍升高。

核心结论

  • RA患者ACS后复发和死亡风险较一般人群增加,且不能仅由二级预防药物使用差异解释。

研究设计与样本

  • 基于1135例RA和3184例非RA患者的队列研究,所有患者在2007–2010年间发生首次ACS。

主要发现

  • 校正基线合并症后,RA患者1年ACS复发HR=1.30(95%CI 1.04–1.62),死亡HR=1.38(95%CI 1.20–1.59)。
  • 全程随访(平均2年)RA患者ACS复发HR=1.27(95%CI 1.06–1.52),死亡HR=1.50(95%CI 1.34–1.68)。
  • 部分ACS亚组中RA患者他汀使用有偏低趋势,其他亚组无明显差异。
  • 在处方模式提示充分启用并坚持二级预防治疗的亚组中,RA患者复发和死亡风险仍升高。

临床怎么用

  • RA患者发生ACS后应视为高复发和死亡风险人群,需加强监测与随访。
  • 二级预防药物的充分启用与坚持不能完全消除RA患者ACS后的超额风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS) and suffer from poorer short-term outcomes after ACS. The aims of this study were to assess long-term outcomes in patients with RA with ACS compared with non-RA patients with ACS, and to investigate whether the use of secondary preventive drugs could explain any differences in ACS outcome. METHODS: We performed a cohort study based on 1135 patients with RA and 3184 non-RA patients who all developed an incident ACS between 2007 and 2010. We assessed 1-year and overall relative risks for ACS recurrence and mortality, as well as prescriptions of standard of care secondary preventive drugs. RESULTS: The risk of ACS recurrence, and of mortality, was increased in RA, both at 1 year after adjusting for baseline comorbidities (HR=1.30(95% CI 1.04 to 1.62) and 1.38(95% CI 1.20 to 1.59), respectively) and throughout the complete (mean 2 years) follow-up (HR=1.27(95% CI 1.06 to 1.52) and 1.50(95% CI 1.34 to 1.68), respectively). Among certain subgroups of ACS, there was a tendency of lower usage of statins, whereas there were no apparent differences in others. The increased rates of ACS recurrence and mortality remained in subgroup analyses of individuals whose prescription pattern indicated both adequate initiation and persistence to secondary preventive treatments. CONCLUSIONS: Patients with RA suffer from an increased risk of ACS recurrence and of death following ACS compared with general population, which in the present study could not readily be explained by differences in usage of secondary preventive drugs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mantel Ä, Holmqvist M, Jernberg T, et al. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28823986. doi:10.1136/annrheumdis-2017-211608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。